The Somogyi effect. Has it ever existed and what harm has it caused?
Explore the source record for details and available documents.
Biomedical subjects
Publications and source records attributed to W Kidson.
Explore the source record for details and available documents.
Little information is available concerning adolescent sexual offenders and their response to treatment. Of 45 sex offenders treated in two studies, 6 were adolescents and 21 of the 39 adults reported that their deviant behavior had commenced before or during adolescence. All 6 adolescents presented for treatment only following detection of their offenses, which in 3 led to legal charges. Of the 39 adults, 12 sought treatment voluntarily. Subjects were randomly allocated to receive covert sensitization, imaginal desensitization, medroxyprogesterone, or imaginal desensitization plus medroxyprogesterone. The response of the adults was equivalent to the best reported in the literature. Seven of the 39 required additional treatment, 3 being charged for further sexual offenses. Four of the 6 adolescents required additional treatment, 3 being charged with further sexual offenses. These differences were statistically significant. Adolescent sexual offenders may be more resistant to treatment because their sexual urges are under more direct hormonal control whereas in adults sexual urges are in part under the control of behavior completion mechanisms. Sexual offenses in adolescence need to be considered as at least as significant as those of adults, and more intensive follow-up treatment appears indicated in their management.
Thirty sex offenders were randomly allocated: 10 to receive medroxyprogesterone therapy (M), 10, imaginal desensitization (ID) and 10 both (ID + M). Twenty-four responded for one year though 3 subsequently relapsed. There were no significant differences in response to the 3 treatments. Four patients who did not respond to the initial treatment and the 3 who relapsed responded to further treatment. Most treated with M maintained heterosexual intercourse at pretreatment frequency. Self-reported reduction in anomalous sexual urges in patients receiving M correlated with reduced testosterone levels one month following treatment, demonstrating that the response was specific and validating the assessment by patients' self-reports. Where cost-effectiveness or time constraints are factors influencing treatment of sex offenders, one of these therapies warrants consideration.
A case of Cushing's disease presenting with avascular necrosis of the femoral heads is described. Eighteen months after the onset of hip symptoms the patient developed pituitary apoplexy and presented to hospital as a medical emergency. Endogenous hypercortisolism is a rare and important cause of avascular necrosis of bone.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
The seven home glucose analysers available on the Australian market were evaluated with respect to accuracy, ease of operation, price and additional features. At the same time, the BM-Test-Glycemie 20-800 dual sticks were assessed. The Boehringer Reflomat and Ames Eyetone can be regarded primarily as hospital instruments. The Ames Dextrometer, the Hypo-Count and both Stan Clark R.A.H.C. Glucose Testers were all adequate for home glucose monitoring. However, the Stan Clark R.A.H.C. Glucose Tester operating on Ames blood glucose reagent strips achieved the highest recommendation over all. The Glucochek was found to be an inconsistent instrument.
Explore the source record for details and available documents.
The urgent admission to hospital of diabetic patients is often precipitated by hypoglycaemia, by vomiting or by ketoacidosis following cessation insulin therapy. By the use of simple agents, such as glucagon, lemonade and quick-acting insulin, such episodes can usually be averted in the early stages by the diabetic, his family and his doctor. These preventive measures keep the diabetic at work or at school and out of hospital, but require the provision of a simple emergency kit.
A new and simple form of insulin therapy for diabetic hyperglycaemia and ketoacidosis has been developed using a continuous intravenous infusion of insulin at a rate of 2.4 U/hr to maintain serum insulin concentration at physiological levels. This rate raises the mean serum insulin to 83 muU/ml and has a therapeutic effect which is not augmented by higher infusion rates. The response to such low doses of insulin indicates a need for a reappraisal of currently held theories about insulin resistance in diabetic ketoacidosis. In 11 diabetic patients with a mean plasma glucose of 514 mg/100 ml this therapy produced continuous falls in plasma glucose at a mean rate of 75 mg/100 ml/hr, and 10 out of 11 patients recovered within eight hours. This form of therapy is simple to institute, not complicated by hypoglycaemia, and avoids the confusion and empiricism of previously described forms of therapy.
Explore the source record for details and available documents.
Twenty-four-hour metabolic profiles were used to compare the efficacy of twice-daily injections of purified porcine and human Actrapid and Monotard insulins (Novo) in six insulin-treated diabetic subjects. Although both insulin regimens resulted in similar plasma glucose profiles, values were lower during the night with porcine insulin treatment. These differences in plasma glucose response may represent an increased effectiveness of porcine insulin. Alternatively, evaluation of the plasma glucose profiles by the mean of the daily differences suggests that inherent day-to-day variations in diabetic control could explain the differences observed. Also, the potency of the porcine insulin used was greater than that of the human insulin and may have contributed to the differences in glucose response. No differences were observed in pyruvate, lactate, total ketones, and insulin profiles over the 24-h period. No adverse reactions to human insulin occurred.
OBJECTIVE: A variety of immune therapies have been used in an attempt to reduce the immune destruction of the insulin secreting beta cells which results in insulin dependent diabetes mellitus (IDDM). This study investigated the use of intravenous gammaglobulin therapy (IVIG) in children and adults with IDDM who participated in a two-year randomised controlled trial which also examined the effect of transfer factor in altering the natural course of IDDM. METHODS: Treatment was administered every two months for the duration of the study. IVIG was given in a dose of 2 g/ kg body weight in divided doses over two days. The other two groups received an intramuscular injection-the control group received normal saline and the transfer factor group received 1 i.u. of transfer factor. Remission rates, beta cell function and treatment side effects were assessed. RESULTS: Compared with the control group, IVIG therapy given every 2 months for 2 years, did not result in an increased number of complete remissions or differences in insulin dose, diabetes control or endogenous insulin secretion assessed as fasting and stimulated C-peptide responses to glucagon and a meal. IVIG therapy was associated with significant side effects. CONCLUSION: It is unlikely that IVIG therapy will be a viable option for immunotherapy in IDDM.